• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Dermapharm Holding (XTRA:DMP) The Latest Update Raises A Bigger Question

    Simply Wall St·11/14/2026 13:25:06
    Listen to the news

    Dermapharm Holding (XTRA:DMP) just released nine month results to September 30, 2026, giving investors fresh detail on how higher sales, slightly lower net profit and improved earnings per share from continuing operations fit together.

    The recent update comes after a choppy period for Dermapharm Holding shares. The 30 day share price return is down 8.56% and the 90 day move is down 10.98%, while the 1 year total shareholder return of 4.40% suggests that short term momentum has softened compared with the longer record.

    Scan how Dermapharm Holding compares with other healthcare businesses that show resilient fundamentals and muted sentiment by running our curated 198 high quality undervalued stocks.

    Dermapharm Holding appears to be a solid healthcare operator based on recent numbers, yet the share price has slipped over the past quarter. Are investors being cautious, or is the current valuation already fair?

    Price-to-Earnings of 13.4x: Is it justified?

    On Simply Wall St's numbers, Dermapharm Holding trades on a P/E of 13.4x, which looks inexpensive compared with both peers and its own fair-value benchmark, given the last close of €35.25.

    The P/E ratio compares what investors are paying today to the earnings the business generates over a year. For a pharmaceutical and healthcare products group like Dermapharm Holding, this is a common way to frame how the market prices its current profitability while also hinting at expectations for future profit growth.

    At 13.4x earnings, the stock is described as "good value" against the European pharmaceuticals average of 20.2x and a peer group average of 19.6x. It also sits below an estimated fair P/E of 16.8x, which points to a meaningful gap the market could close if sentiment or earnings assumptions shift closer to that fair ratio level.

    Explore the SWS fair ratio for Dermapharm Holding.

    Result: Price-to-Earnings of 13.4x (UNDERVALUED)

    Still, Dermapharm Holding faces risks if regulatory pressures squeeze pricing on off patent drugs or if longer term share returns weighing on sentiment keep investors cautious.

    Find out about the key risks to this Dermapharm Holding narrative.

    Another view on Dermapharm Holding's value

    The P/E points to Dermapharm Holding looking inexpensive, but the SWS DCF model is far more aggressive. It estimates a future cash flow value of €99.14 per share versus the current €35.25, which signals a very wide undervaluation gap that is hard to ignore.

    That kind of spread can reflect either a generous cash flow outlook or a market that is heavily discounting risks around debt, regulation and long term growth. The key question for you is simple: which side of that gap feels more realistic?

    Look into how the SWS DCF model arrives at its fair value.

    DMP Discounted Cash Flow as at Nov 2026
    DMP Discounted Cash Flow as at Nov 2026

    Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Dermapharm Holding for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 198 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

    Next Steps

    Sentiment around Dermapharm Holding in this update may feel mixed. This is exactly why it helps to stress test the numbers yourself and move quickly from headline impressions to actual evidence. To weigh the potential risks against the possible rewards in one place, review the 4 key rewards and 2 important warning signs.

    Looking for more investment ideas beyond Dermapharm Holding?

    If Dermapharm Holding has caught your attention, do not stop there. Spread your research across other opportunities so you are not relying on a single story.